Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Dillon R. Flebbe Clear advanced filters

  • Viral sequencing reveals subclinical infections in animals challenged with simian immunodeficiency virus even in the presence of potent neutralizing antibodies, with implications for clinical trials of antiviral agents against human immunodeficiency virus.

    • Christopher A. Gonelli
    • Hannah A. D. King
    • Mario Roederer
    ResearchOpen Access
    Nature
    Volume: 639, P: 205-213

  • SARS-CoV-2 evolution poses a risk to vaccine and antiviral drug efficacy. Here, Gagne et al. report the development of a variant-agnostic protein, RBD-62, with enhanced ACE2 binding obtained through in vitro evolution and show that RBD-62 inhalation protects nonhuman primates against SARS-CoV-2 Delta challenge.

    • Matthew Gagne
    • Barbara J. Flynn
    • Daniel C. Douek
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-13

  • The beta variant (B.1.351) is to date the most resistant to neutralization of the SARS-CoV-2 variants. Using nonhuman primates, Seder and colleagues demonstrate that double vaccination with a high dose of the lipid nanoparticle vaccine mRNA-1273 protects against infection with the beta variant.

    • Kizzmekia S. Corbett
    • Anne P. Werner
    • Robert A. Seder
    Research
    Nature Immunology
    Volume: 22, P: 1306-1315